• Something wrong with this record ?

Patients with REM sleep behavior disorder have higher serum levels of allantoin

L. Hasíková, J. Závada, T. Serranová, L. Kotačková, P. Kozlík, K. Kalíková, J. Trnka, D. Zogala, K. Šonka, E. Růžička, P. Dušek

. 2021 ; 90 (-) : 38-43. [pub] 20210730

Language English Country Great Britain

Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22012269

INTRODUCTION: Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with an increased risk of developing Parkinson's disease (PD). Low uric acid (UA) levels are associated with the risk of development and progression of PD. Allantoin is the major oxidation product of UA and is considered as a biomarker of oxidative stress. We aimed to compare serum levels of UA, allantoin, and allantoin/UA ratio in RBD patients with those in healthy controls, and to examine their associations with clinical severity. METHODS: We evaluated serum levels of UA, allantoin, and allantoin/UA ratio in 38 RBD patients (one female, mean age 66.8 (SD 6.3) years) and in 47 controls (four females, 66.8 (7.6) years). All RBD patients were assessed according to an examination protocol, which included structured interview, Montreal Cognitive Assessment (MoCA), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and dopamine transporter single-photon emission computed tomography (DAT-SPECT). The lower putaminal binding ratio from both hemispheres was used for analysis. RESULTS: Mean serum allantoin concentration and allantoin/UA ratio were significantly increased in the RBD group compared to controls (2.6 (1.8) vs. 1.4 (0.7) μmol/l, p = 0.0004, and 0.008 (0.004) vs. 0.004 (0.002), p < 0.0001, respectively). There were no significant differences in UA levels between the two groups. No significant associations between any biochemical parameter and RBD duration, putaminal binding ratio on DAT-SPECT, MDS-UPDRS, or MoCA score were found. CONCLUSION: Serum allantoin and allantoin/UA ratio are increased in RBD patients in comparison to controls, which may reflect increased systemic oxidative stress in prodromal synucleinopathy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012269
003      
CZ-PrNML
005      
20220506130300.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.parkreldis.2021.07.031 $2 doi
035    __
$a (PubMed)34352609
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hasíková, Lenka $u Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Patients with REM sleep behavior disorder have higher serum levels of allantoin / $c L. Hasíková, J. Závada, T. Serranová, L. Kotačková, P. Kozlík, K. Kalíková, J. Trnka, D. Zogala, K. Šonka, E. Růžička, P. Dušek
520    9_
$a INTRODUCTION: Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with an increased risk of developing Parkinson's disease (PD). Low uric acid (UA) levels are associated with the risk of development and progression of PD. Allantoin is the major oxidation product of UA and is considered as a biomarker of oxidative stress. We aimed to compare serum levels of UA, allantoin, and allantoin/UA ratio in RBD patients with those in healthy controls, and to examine their associations with clinical severity. METHODS: We evaluated serum levels of UA, allantoin, and allantoin/UA ratio in 38 RBD patients (one female, mean age 66.8 (SD 6.3) years) and in 47 controls (four females, 66.8 (7.6) years). All RBD patients were assessed according to an examination protocol, which included structured interview, Montreal Cognitive Assessment (MoCA), Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and dopamine transporter single-photon emission computed tomography (DAT-SPECT). The lower putaminal binding ratio from both hemispheres was used for analysis. RESULTS: Mean serum allantoin concentration and allantoin/UA ratio were significantly increased in the RBD group compared to controls (2.6 (1.8) vs. 1.4 (0.7) μmol/l, p = 0.0004, and 0.008 (0.004) vs. 0.004 (0.002), p < 0.0001, respectively). There were no significant differences in UA levels between the two groups. No significant associations between any biochemical parameter and RBD duration, putaminal binding ratio on DAT-SPECT, MDS-UPDRS, or MoCA score were found. CONCLUSION: Serum allantoin and allantoin/UA ratio are increased in RBD patients in comparison to controls, which may reflect increased systemic oxidative stress in prodromal synucleinopathy.
650    _2
$a senioři $7 D000368
650    _2
$a alantoin $x krev $7 D000481
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxidační stres $7 D018384
650    _2
$a porucha chování v REM spánku $x krev $7 D020187
650    _2
$a synukleinopatie $x krev $7 D000080874
650    _2
$a jednofotonová emisní výpočetní tomografie $7 D015899
650    _2
$a kyselina močová $x krev $7 D014527
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Závada, Jakub $u Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Serranová, Tereza $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Kotačková, Lenka $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Kozlík, Petr $u Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Kalíková, Květa $u Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Trnka, Jiří $u Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Zogala, David $u Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Šonka, Karel $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Růžička, Evžen $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Dušek, Petr $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Electronic address: petr.dusek@vfn.cz
773    0_
$w MED00006198 $t Parkinsonism & related disorders $x 1873-5126 $g Roč. 90, č. - (2021), s. 38-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34352609 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130252 $b ABA008
999    __
$a ok $b bmc $g 1789733 $s 1163470
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 90 $c - $d 38-43 $e 20210730 $i 1873-5126 $m Parkinsonism & related disorders $n Parkinsonism Relat Disord $x MED00006198
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options